0.00Open0.04Pre Close0 Volume128 Open Interest82.00Strike Price0.00Turnover3157.23%IV5.19%PremiumNov 22, 2024Expiry Date0.00Intrinsic Value100Multiplier-8DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.0248Delta0.0133Gamma1949.75Leverage Ratio-88.6451Theta0.0000Rho48.30Eff Leverage0.0001Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet